Elvia Cowan - Jul 8, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol
PCVX
Transactions as of
Jul 8, 2024
Transactions value $
-$270,400
Form type
4
Date filed
7/9/2024, 05:15 PM
Previous filing
Mar 4, 2024
Next filing
Jul 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $130K +5K +39.3% $25.92 17.7K Jul 8, 2024 Direct F1
transaction PCVX Common Stock Sale -$400K -5K -28.21% $80.00 12.7K Jul 8, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -5K -3.88% $0.00 124K Jul 8, 2024 Common Stock 5K $25.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2024.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023.
F3 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.